ISFIYA, Israel, May 12, 2015 /PRNewswire/ -- Check-Cap Ltd. (Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of a preparation-free ingestible imaging capsule screening for colorectal cancer, today announced that Guy Neev, Chief Executive Officer, will present at the 2015 Marcum MicroCap Conference on Thursday, May 28, 2015 in New York City.
Mr. Neev's presentation is scheduled to begin at 11:30 a.m. EDT. To access a live webcast of this presentation, please visit http://ir.check-cap.com/. A replay will be available for 90 days following the presentation.
Check-Cap's imaging capsule is designed for the detection of colorectal cancer and clinically-significant pre-cancerous polyps. Unlike other colon screening methods, Check-Cap's imaging capsule can be used without prior fasting or cleansing of the colon. This provides a significant advantage over current procedures—such as optical colonoscopy, computer tomographic colonography (CTC) and other capsule-based products—which are either invasive, require the patient to fast for several hours before the procedure, or involve other uncomfortable bowel preparation.
Colorectal cancer is the second leading cause of death from cancer in the United States, but roughly one-half of Americans over the age of 50 do not undergo colon cancer screening due in large part to the pain, discomfort and embarrassment related to current screening methods. Check-Cap believes that its preparation-free alternative will increase the number of individuals willing to undergo colorectal cancer screening.
About the 2015 Marcum MicroCap Conference
The Marcum MicroCap Conference will be held on May 27-28 at the Grand Hyatt New York. The conference is dedicated to providing a forum where publicly traded companies under $500 million in market capitalization can network with the investment community. This event attracts fund managers and high net worth investors who focus on small cap equities. More than 2,000 participants from all segments of the microcap market are expected to participate in this year's conference.
About Check-Cap
Check-Cap is a clinical stage medical diagnostics company focused on the development of gastrointestinal imaging devices. The Company's lead product is an endoscopy capsule with a colon imaging system for colorectal cancer and clinically-significant pre-cancerous polyps that utilizes proprietary, ultra-low-energy X-ray-based measurement technology to safely generate high-resolution, 3-dimensional imagery of the colon without cleansing or other aggressive bowel preparation. This solution is designed to increase compliance with screening recommendations. The Check-Cap imaging system is not cleared for marketing in any jurisdiction.
Legal Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements." Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Special Note On Forward-looking Statements" and "Risk Factors" in the Company's Registration Statement on Form F-1 and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
CONTACT:
Investors
David Carey
Lazar Partners Ltd.
212-867-1768
dcarey@lazarpartners.com
SOURCE Check-Cap Ltd.